JPRN-jRCT1080222105未知4 期
A 24-month, phase IV, randomized, double masked, multi-center study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy
ovartis Pharma K.K.0 个研究点目标入组 320 人开始时间: 2013年6月10日最近更新:
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Confirmed diagnosis of symptomatic macular PCV in the study eye
- •A qualifying visoin score at study entry
- •Aqualifying lesion size in the study eye at study entry
排除标准
- •Active inflammation or infection in the study eye
- •Uncontrolled intraocular pressure in the study eye
- •Ocular condition in the study eye which may impact vision and confound study outcomes
- •Prior treatment of the study eye with anti-VEGF therapy, verteporfin PDT, other laser and surgical interventions, intraocular corticosteroids
研究者
相似试验
已完成
3 期
A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/or anatomical criteria, in patients with neovascular age-related macular degeneration (CRFB002A2405, OCTAVE study)10042261macular degenerationNL-OMON38832ovartis Pharma BV20
进行中（未招募）
不适用
Efficacy and safety of two different treatment patterns of ranibizumab in patients with wet AMDEUCTR2011-004959-39-LTovartis Pharma Services AG670
进行中（未招募）
不适用
Efficacy and safety of two different treatment patterns of ranibizumab in patients with wet AMDVisual impairment due to neovascular AMDMedDRA version: 14.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 100000004853EUCTR2011-004959-39-ITovartis Farma670
进行中（未招募）
1 期
Efficacy and safety of two different treatment patterns of ranibizumab in patients with wet AMDVisual impairment due to neovascular AMDMedDRA version: 19.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 100000004853EUCTR2011-004959-39-PTovartis Pharma Services AG670
进行中（未招募）
1 期
Efficacy and safety of two different treatment patterns of ranibizumab in patients with wet AMDEUCTR2011-004959-39-FRovartis Pharma Services AG670